

ISSN-0973-9122 (Print) • ISSN-0973-9130 (Electronic)

Volume 15 / Number 1 / January-March 2021



Indian Journal of Forensic Medicine & Toxicology

Website: www.ijfmt.com



Official Organ of Indian Association of Medico-Legal Experts (Regd.)

Indian Journal of Forensic Medicine & Toxicology

EDITOR in Chief

Prof. R K Sharma

Formerly at All India Institute of Medical Sciences, New Delhi, E-mail: editor.ijfmt@gmail.com

EDITOR

Prof. Dr. Adarsh Kumar

Forensic Medicine & Toxicology, AIIMS, New Delhi

INTERNATIONAL EDITORIAL ADVISORY BOARD

1. **Prof Mete Gulmen** Cukurova University, TURKEY
2. **Prof. Leandro Duarte De Carvalho**, Minas Gerais, Belo Horizonte, Brazil
3. **Prof. Donata Favretto** (Full Professor) Forensic Toxicology at University of Padova, Italy
4. **Prof. Babak Mostafazadeh** Department of Forensic Medicine & Toxicology, Shahid Beheshti University of Medical Sciences, Tehran-Iran
5. **Prof Halis Dokgoz**, Mersin University, TURKEY
6. **Prof Jozef Sidlo**, Comenius University, Bratislava, SLOVAKIA
7. **Dr. Rahul Pathak** (Lecturer) Forensic Science, Dept of Life Sciences Anglia Ruskin University, Cambridge, United Kingdom
8. **Dr. Hareesh** (Professor & Head) Forensic Medicine, Ayder Referral Hospital, College of Health Sciences, Mekelle University, Mekelle Ethiopia East Africa
9. **Dr. Mokhtar Ahmed Alhrani** (Specialist) Forensic Medicine & Clinical Toxicology, Director of Forensic Medicine Unit, Attorney General's Office, Sana'a, Yemen
10. **Dr. Sarathchandra** Kodikara (Senior Lecturer) Forensic Medicine, Department of Forensic Medicine, Faculty of Medicine, University of Peradeniya, Sri Lanka
11. **Dr Noha A. Magdie El Rafie**, Forensic Toxicology, Ain Shams University, Cairo, EGYPT

SCIENTIFIC COMMITTEE

1. **Prof Udai Pratap Singh**, Department of Anthropology Lucknow University Lucknow
2. **Dr Anil Rahule** (Associate Professor) Dept of Anatomy, Govt Medical College Nagpur
3. **Dr Shankar Bakkanwar** (Associate Professor) Forensic Medicine, Kasturba Medical College, Manipal, Karnatakad
4. **Dr K. Ravikumar** Raksha Shakti University, Ahmedabad, Gujrat.
5. **Dr. Pragnesh Parmar** (Associate Professor) Forensic Medicine, Valsad, Gujrat
6. **Dr Vandana Mudda** (Awati) (Associate Prof) Dept of FMT, M.R. Medical College, Gulbarga, Karnataka,
7. **Dr. Asha Srivastava** (Senior Scientific Officer) Forensic Psychology, Central Forensic Science Laboratory, CBI, Delhi
8. **Dr. Lav Kesharwani** (Asst.Prof.) School of Forensic Science, Sam Higginbottom Institute of Agriculture Technology & Sciences, Allahabad U.P,
9. **Dr. Anu Sharma** (Associate Prof) Dept of Anatomy, DMCH, Ludhiana (PB)
10. **Dr. Shalini Gupta** (Prof) Oral Pathology and Microbiology, Dental Sciences King George Medical University, Lucknow, UP
11. **Dr Rituja Sharma**, Associate Prof, Law Banasthali Vidyapeeth Jaipur

"Indian Journal of Forensic Medicine & Toxicology" is peer reviewed quarterly journal. It deals with Forensic Medicine, Forensic Science, Toxicology, DNA fingerprinting, sexual medicine and environment medicine. It has been assigned International standard serial No. p-0973-9122 and e- 0973-9130. The Journal has been assigned RNI No. DELENG/2008/21789. The journal is indexed with Index Copernicus (Poland) and is covered by EMBASE (Excerpta Medica Database). The journal is also abstracted in Chemical Abstracts (CAS) database (USA). The journal is also covered by EBSCO (USA) database. The Journal is now part of UGC, DST and CSIR Consortia. It is now official publication of Indian Association of Medico-Legal Experts (Regd.).

NATIONAL EDITORIAL ADVISORY BOARD

Chairman

Prof Sudhir K Gupta - Head, Department of Forensic Medicine
All India Institute of Medical Sciences, New Delhi

Members

1. **Prof. SK Dhatarwal**, Forensic Medicine, PGIMS, Rohtak, Haryana
2. **Prof. N K Aggrawal** Forensic Medicine, UCMS, Delhi
3. **Prof Ajay Ghangale** Forensic Medicine Dr DY Patil Medical College, Pune, Maharashtra
4. **Dr. Amar Jyoti** Patwory Professor, Forensic Medicine NEIGRIHMS, Shillong
5. **Dr S. Venkata Raghava** Professor, Forensic Medicine, Bangalore Medical College, Bengaluru
6. **Prof Praveen Arora**, Professor Department of Forensic Medicine & Toxicology, SAIMS, Indore
7. **Dr. Pankaj Datta** (Principal & Head) Department of Prosthodontics, Indraprastha Dental College & Hospital, Ghaziabad
8. **Dr. Mahindra Nagar** (Head) Department of Anatomy, UCMS & GTB Hospital, Delhi
9. **Dr. Virender Kumar Chhoker** Professor Forensic Medicine and Toxicology, Santosh Medical College, Ghaziabad, UP
10. **Dr. Dayanand G Gannur** (Professor) Department of Forensic Medicine & Toxicology, Shri BM Patil Medical College, Hospital & Research centre, Bijapur, Karnataka
11. **Dr. Alok Kumar** Professor Department of Forensic Medicine & Toxicology, UP Rural Institute of Medical Sciences and Research, Saifai, Etawah, U.P.

Print-ISSN:0973-9122 Electronic - ISSN: 0973-9130

Frequency: Quarterly, © All Rights reserved The views and opinions expressed are of the authors and not of the Indian Journal of Forensic Medicine & Toxicology. Indian Journal of Forensic Medicine & Toxicology does not guarantee directly or indirectly the quality or efficacy of any products or service featured in the advertisement in the journal, which are purely commercial.

Website: www.ijfmt.com

Editor

Dr. R.K. Sharma
Institute of Medico-legal Publications
Logix Office Tower, Unit No. 1704, Logix City Centre Mall, Sector- 32, Noida
- 201 301 (Uttar Pradesh)

Printed, published and owned by

Dr. R.K. Sharma
Institute of Medico-legal Publications
Logix Office Tower, Unit No. 1704, Logix City Centre Mall, Sector- 32, Noida
- 201 301 (Uttar Pradesh)

Published at

Institute of Medico-legal Publications
Logix Office Tower, Unit No. 1704, Logix City Centre Mall, Sector- 32, Noida
- 201 301 (Uttar Pradesh)

213. Non-Hodgkin's Lymphoma in the Parotid Gland Similar to Benign Lymphoepithelial Lesion: A Case Indonesian Male 1334
Muhammad Arif Sudioanto Utama, Widodo Ario Kentjono
214. The Influence of the GETAR Spiritual Approach on Smoking Behavior of Junior High School Students in Palu City, Indonesia 1340
Muhammad Ryman Napirah, Ridwan Amiruddin, Sukri Palutturi, Stang, Aminuddin Syam, Darmawansyah, Rosmala Nur
215. Teaching-Learning Styles & Aids Student's Preferences among first Year Undergraduate Medical Students in the College of Medicine, University of Missan, Iraq 1346
Mustafa M. Al-Yassiry, Farah K. Aloraibi, Haider Saadoon Qasim Alhilfi
216. The Exposure of Gap Competence causes in Stunting Children Ages 0-12 Months in Makassar Indonesia: Cross-Sectional Study 1354
Mustamin, Sirajuddin, Mahmud
217. The Interleukin-6 (rs1800797) Variant in Healthy Individuals at Medan City, North Sumatera Province 1361
Mutiara Indah Sari, Siti Syarifah, Milahayati Daulay, Zaimah Z Tala*
218. Effect of *Malus sylvestris* Extract on Histopathological Features of Hypercholesterolemic Wistar Rat (*Rattus norvegicus*) Fatty Liver 1367
Nadhifa Tanesha Aufazhafarin, Alphania Rahniayu, Ema Qurnianingsih, Arifa Mustika
219. Hyperglycemia in Childhood Acute Lymphoblastic Leukemia During Induction Chemotherapy 1373
Nengcy Erlina Tasik Rerung, Andi Cahyadi, Nur Rochmah, Maria Christina Shanty Larasati, Mia Ratwita Andarsini, Muhammad Faizi
220. Correlation of Hot Work Climate with Dehydration on Bricks Workers 1379
Nesya Shera Putri Iksani, Endang Dwiyaniti
221. Equality of Suffrage for People with Mental Disorders in Malang City 1387
Nofti Sri Utami, Nanik Prasetyoningsih, Kuswanto Kuswanto
222. Determining the Exposure of Benzene, Toluene, Xylene (in Condensate) in a Chemical Laboratory of Natural Gas Company by Chemical Health Risk Assessment (CHRA) 1392
Nora Putri Sabilla, Noeroel Widajati
223. A questionnaire-based Study of Knowledge and Attitude in Healthcare Professionals about Child Sexual Abuse related to POCSO (Protection of Children from Sexual Offences) Act: A Cross-sectional Study 1398
Nowsheen Goni, Mukesh Kumar Goyal, Chahat Shikarwar, Chahat Jangir
224. Level of Knowledge and Family Support toward Medication Adherence among Patient with Diabetes Mellitus in Malang, Indonesia 1406
Nur Lailatul Masruroh, Alifia Fatehana Pangastuti, Nur Melizza, Anggraini Dwi Kurnia

Effect of *Malus sylvestris* Extract on Histopathological Features of Hypercholesterolemic Wistar Rat (*Rattus norvegicus*) Fatty Liver

Nadhifa Tanesha Aufazhafarin¹, Alphania Rahniayu², Ema Qurnianingsih³, Arifa Mustika⁴

¹Student, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, ²Lecturer, Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, ³Lecturer, Department of Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, ⁴Lecturer, Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Abstract

Objective: To evaluate the effect of *Malus sylvestris* extract on improving the degree of steatosis and portal inflammation histopathological features of hypercholesterolemic *Rattus norvegicus* strain wistar. **Method:** Forty-two male rats were divided into 6 groups randomly. Hypercholesterolemic fatty liver induced by giving high-fat diet (HFD) for 46 days on groups 1 to 5, while group 6 given standard diet with the same amount of time. Simvastatin was administered in group 2 at a dose of 0.36 mg/day. Groups 3, 4, and 5 were given *Malus sylvestris* extract (MSE) as a treatment at doses of 90 mg/day, 180 mg/day, and 360 mg/day in sequential order. Simvastatin and MSE were administered for 14 days, from day 33 to 46. On day 47, all rats were sacrificed and the liver was removed for histopathological slides preparation with hematoxylin-eosin (HE) staining. Histopathological results were analyzed using Kruskal Wallis test followed by Mann Whitney test. **Result:** Histopathological analysis showed that *Malus sylvestris* extract improved steatosis and portal inflammation features compared to HFD-fed rats in group 1 ($p < 0,05$). **Conclusion:** *Malus sylvestris* extract improved the degree of steatosis and portal inflammation histopathological features of hypercholesterolemic rat fatty liver.

Keywords: Fatty Liver, Histopathological, Hypercholesterolemic, *Malus sylvestris*, Rat.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is the accumulation of excess fat in the liver with more than 5% of hepatocytes containing visible lipid vacuoles or steatosis affecting at least 5% of the liver weight without heavy alcohol consumption or other secondary causes¹. The disease can progress from harmless simple non-alcoholic steatosis (NAS) to non-alcoholic steatohepatitis (NASH), a form of inflammation that damages the liver cells². Liver cell damage then can lead to fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC), which require liver transplantation³. Although cirrhosis due to hepatitis C is the leading cause of liver transplantation in the United States, NAFLD rank the second. As prevalence continues to increase, NAFLD will become major health problems and the

major cause of liver transplantation in the future⁴. This will also increase the demand for liver transplantation with fewer good-quality organs, as more donors have steatotic livers⁵.

NAFLD has emerged as the most common chronic liver disease in developed countries. However, the prevalence of NAFLD continues to increase even in developing countries due to worldwide epidemic of obesity and other metabolic syndromes⁶. The prevalence of NAFLD worldwide is approximately 25.24%, with highest prevalence in the Middle East (31.79%) and South America (30.45%)⁷. In Asia, there is almost 10% increase in prevalence from the initial 25.28% in 1999-2005 to 33.90% in 2012-2017⁸. The data have shown that the cases will always increase and become a problem not only in Western countries but also in Asia

due to urbanization. Urbanization will lead to sedentary lifestyle with excessive dietary consumption resulting in obesity, a risk factor for NAFLD⁹. Apart from obesity, NAFLD also accompanied by hyperlipidemia, hypertension, type 2 diabetes, cardiovascular disease, and other metabolic syndromes that may affect not only the liver but also the person's systemic condition^{3,7}.

Environmental factors play an important role in the development of NAFLD, such as eating habits, daily activities, and socioeconomic factors¹⁰. Dietary patterns of high sodium and fat with low consumption of fresh fruit have been found in NAFLD patients¹¹. By eating fruits and vegetables, especially apples, can reduce the risk of NAFLD due to fiber and chemical contents in apples such as flavonoids, polyphenols, and carotenoids, which have antioxidant and anti-inflammatory effects to prevent and protect the liver from NAFLD¹². So far, there are only few studies regarding to the effect of apples on treating NAFLD and there are no studies specifically using *Malus sylvestris*. Hence, this study aimed to evaluate the effect of *Malus sylvestris* extract on improving histopathological features of hypercholesterolemic Wistar rat (*Rattus norvegicus*) fatty liver.

Materials and Methods

Malus sylvestris collection and extraction:

Malus sylvestris were collected from apple farm in Junggo Village, Bumiaji, Batu, Indonesia. The apples were washed, drained, and weighed. *Malus sylvestris* with their skins were cut into thin strips and air-dried in the shade. To maximize the drying process, apple slices were roasted at 45°C for about 48 hours or until completely dried. The dried apple slices were crushed in a blender and sieved into powder. *Malus sylvestris* powder then extracted with 96% ethanol using percolation technique. Extraction process was continued with rotary evaporator to removed the alcohol content and a thick extract will be produced.

Experimental Animal:

Forty-two male Wistar rats around 2-3 months old weighing between 125-200g were used for the study. They were cared for in clean well-ventilated cages with light/dark cycle 12 h respectively and were given water

and either a standard or high-fat diet (HFD) *ad libitum*. Before the experiment began, they will be acclimatized for seven days with a standard diet in the Experimental Animal Unit of Pharmacology Laboratory within Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

Experimental design¹³:

Forty-two Wistar rats were randomized and divided into 6 groups each containing 7 rats. Group I received HFD served as negative control rats. Group II received HFD and simvastatin at dose of 0,36 mg/day served as positive control rats. Group III received HFD and *Malus sylvestris* extract at dose of 90 mg/day. Group IV received HFD and *Malus sylvestris* extract at dose of 180 mg/day. Group V received HFD and *Malus sylvestris* extract at dose of 360 mg/day. Group VI received standard diet served as normal control rats. Standard or high-fat diet for the rats was given for 46 days. Simvastatin and *Malus sylvestris* extract (MSE) were administered orally by using oral gavage for 14 days (day 33-46). On day 47, all animals were euthanized using chloroform and sacrificed by cervical dislocation. The liver was removed for histopathological analysis.

Histopathological studies:

All livers were fixed by immersing it in 10% neutral buffer formalin for 24 hours. Histopathological preparations continued with dehydration, clearing, impregnation, and then making paraffin blocks, which were cut by microtome with thickness of 4-5 µm. The tissue slices were attached to glass object and then stained with hematoxylin-eosin (HE). Histopathological slides were observed per field of view under light microscope at 100x magnification to determine the observed area and 400x magnification to observe the cells more clearly. Observation of liver cells used semi quantitative scoring system to evaluate steatosis and portal inflammation features¹⁴.

Statistical Analysis

Statistical analysis was performed using SPSS 20 for windows and the results were represented as mean. All results were analyzed statistically by Kruskal Wallis test, followed by Mann Whitney test to determine the significant difference between groups.

Result

The results were considered to be statistically significant when $p < 0.05$. Mean rank value of steatosis and portal inflammation from statistical analysis can be seen in Table 1.

Table 1: Effect of MSE on histopathological features of hypercholesterolemic rats

Histopathology Features	Group I	Group II	Group III	Group IV	Group V	Group VI
Steatosis	33.71a	19.86b	22.64b	18.00b	17.07b	14.29b
Portal Inflammation	34.86a	20.14b	20.14b	18.33b	14.71b	17.43b

Values are represented in mean. Different superscript letters indicate significant difference ($p < 0.05$).

Under the microscope, rats in normal control groups showed normal liver histology with minimal steatosis and portal inflammation features (Fig. 1F and 2F). Rats fed with HFD in positive control group showed severe fat vacuoles accumulation (steatosis) in liver cell cytoplasm (Fig. 1A) as well as inflammatory cell infiltration in portal area (Fig. 2A). However, Fig. 1B and 2B showed reduced fatty change and inflammatory cell in the portal area in simvastatin group, this suggest that the drug could alleviate steatosis and portal inflammation. All doses of MSE also showed similar result as simvastatin group by improving steatosis (Fig. 1C, 1D, 1E) and portal inflammation (Fig. 2C, 2D, 2E) features compared to positive control group.




Figure 1. Effect of MSE on improving steatosis features in liver histopathology

(A) Liver tissue of HFD induced rats. Black arrows indicate fatty vacuoles in liver cell cytoplasm (steatosis). (B) Liver tissue of rats treated with simvastatin. (C) Liver tissue of rats treated with MSE at doses of 90 mg/day. (D) Liver tissue of rats treated with MSE at doses of 180 mg/day. (E) Liver tissue of rats treated with MSE at doses of 360 mg/day. (F) Liver tissue of normal control rats.




Figure 2. Effect of MSE on improving portal inflammation features in liver histopathology

(A) Liver tissue of HFD induced rats. Black arrows indicate inflammatory cells that fill the portal area. (B) Liver tissue of rats treated with simvastatin. (C) Liver tissue of rats treated with MSE at doses of 90 mg/day. (D) Liver tissue of rats treated with MSE at doses of 180 mg/day. (E) Liver tissue of rats treated with MSE at doses of 360 mg/day. (F) Liver tissue of normal control rats.

Discussion

Accumulation of lipid droplets in liver cells can be macrovesicular or microvesicular, which is rich in triacylglycerol (TAG). Liver does not store TAG in normal conditions, but exposure to stress due to excessive intake of fat or carbohydrates such as HFD consumption may cause fat accumulation in the liver¹⁵. This is associated with lipotoxicity because it increases mitochondrial stress. Mitochondrial dysfunction increased reactive oxygen species (ROS) production, which reduces antioxidants that act as a defense against oxidative stress in the liver¹⁶. Ongoing oxidative stress may lead to lipid peroxidation that causes lesions to liver cells leading to degeneration and necrosis¹⁷. The end products of lipid peroxidation, malondialdehyde, have chemoattractant properties that activate stellate cells as collagen producers and pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF- α) that activates c-Jun N-terminal kinases (JNK) pathway and nuclear factor kappa light chain enhancer of activated B cells (NF- κ B), induce the release for more pro-inflammatory cytokines mediating liver inflammation¹⁸. This may lead to NASH with mixed lesion of necrosis, inflammatory

infiltrates, and fibrosis, in addition to steatosis¹⁹.

This study showed that MSE give hepatoprotective effect by improving steatosis and portal inflammation features compared to rats fed with HFD. This might be due to the presence of polyphenols and pectin in *Malus sylvestris*, which have metabolic regulatory, antioxidant, and anti-inflammatory properties. Polyphenols reduce TAG accumulation by various mechanisms, including inhibition of lipogenesis and promotion of fatty acid catabolism by down-regulating sterol regulatory element-binding protein 1c (SREBP-1c), which has a major role in lipogenesis²⁰. Dietary fiber has also been shown to reduce the risk of NAFLD. Pectin is one of the dissolved dietary fibers found in apple in high concentrations, which increase the amount of intestinal microbiota that ferments pectin into short chain fatty acids (SCFAs) in large intestine²¹. SCFAs containing 2-5 carbons such as propionate inhibit carbohydrate response element binding protein (ChREBP), acetyl-coenzyme A carboxylase (ACC), and fatty acid synthase (FAS) which plays role in liver lipogenesis²².

Polyphenols showed anti-inflammatory effect through several signaling pathways, such as by suppressing the activation of the NF- κ B pathway, decreasing JNK phosphorylation protein, reducing levels of serum inflammatory cytokines, and increasing antioxidant defenses via the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway^{23,24}. In addition to polyphenols, other components in apples, such as pectin and its fermented products (SCFAs), can inhibit the secretion of TNF- α and NF- κ B activation that suppress the progression of liver damage²⁵.

The ability of apple extract on improving histopathological features of fatty liver can also be seen from previous studies with similar results with this study^{26,27,28}. In addition, apple extract also showed lower levels of serum total cholesterol, low-density lipoprotein cholesterol (LDL-c), and triglycerides (TG) compared to Western diet (high fat and sugar) group²⁸. Further research is needed to investigate certain active ingredient isolates in *Malus sylvestris* extract, which have dominant role on ameliorating NAFLD histopathological features. It is also necessary to examine the effects of *Malus sylvestris* extract other than histopathological studies, as the diagnosis of NAFLD may be made by other tests²⁹.

Conclusion

Malus sylvestris extract improve the degree of steatosis and portal inflammation histopathological features of hypercholesterolemic rat fatty liver. This shows that *Malus sylvestris* provide hepatoprotective effect that could act as a potential treatment for NAFLD.

Conflict of Interest: The authors declare no conflict of interest.

Ethical Clearance: This study had been approved by Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

Source of Funding: Self funding.

Acknowledgements: The authors are thankful to the authorities of Faculty of Medicine, Universitas Airlangga for providing the necessary facilities for this experiment.

References

1. Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World Journal of Hepatology. 2015; 7(6): 846–858.
2. Ahmed M. Non-alcoholic fatty liver disease in 2015. World Journal of Hepatology. 2015; 7(11): 1450–1459.
3. Metrakos P, Nilsson T. Non-alcoholic fatty liver disease--a chronic disease of the 21st century. Journal of Biomedical Research. 2018; 32(5): 327–335.
4. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148(3): 547–555.
5. Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, Burra P. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?. World Journal of Gastroenterology. 2018; 24(14): 1491–1506.
6. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. Journal of Clinical and Translational Hepatology. 2017; 5(4): 384–393.
7. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73–84.
8. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VWS, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology. 2019; 4 (5): 389-398.
9. Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. Journal of hepatology. 2017; 67(4): 862-873.
10. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology. 2018; 15(1): 11-

- 20.
11. McCarthy EM, Rinella ME. The Role of Diet and Nutrient Composition in Nonalcoholic Fatty Liver Disease. *Journal of the Academy of Nutrition and Dietetics*. 2012; 112(3): 401-409.
12. Corcoran MP, McKay DL, Blumberg JB. Flavonoid basics: Chemistry, sources, mechanisms of action, and safety. *Journal of Nutrition in Gerontology and Geriatrics*. 2012; 31(3): 176-189.
13. Nurman Z, Masrul, Sastri S. Pengaruh Pektin Buah Apel (*Malus Sylvestris Mill*) Terhadap Kadar LDL Kolesterol pada Tikus Putih Jantan (*Rattus Novergicus*) Hiperkolesterolemia. *Jurnal Kesehatan Andalas*. 2017; 6(3): 679.
14. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *The American Journal of Gastroenterology*. 1999; 94(9), 2467-2474.
15. Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and prevention of hepatic steatosis. *Gastroenterology and Hepatology*. 2015; 11(3): 167-175.
16. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. *Hepatology*. 2010; 52(2): 774-788.
17. Aguirre L, Portillo MP, Hijona E, Bujanda L. Effects of resveratrol and other polyphenols in hepatic steatosis. *World Journal of Gastroenterology*. 2014; 20(23): 7366-7380.
18. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. *Trends In Endocrinology and Metabolism*. 2008; 19(10): 371-379.
19. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. *Journal of Gastroenterology and Hepatology*. 2002; 17: S186-S190
20. Rodriguez-Ramiro I, Vauzour D, Minihane AM. Polyphenols and non-alcoholic fatty liver disease: Impact and mechanisms. In *Proceedings of the Nutrition Society*. 2016; 75(1): 47-60.
21. Tian L, Scholte J, Borewicz K, van den Bogert B, Smidt H, Scheurink AJ, Gruppen H, Schols HA. Effects of pectin supplementation on the fermentation patterns of different structural carbohydrates in rats. *Molecular nutrition & food research*. 2016; 60(10): 2256-2266.
22. Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. *Gut*. 2016; 65(12): 2035-2044.
23. Li S, Tan HY, Wang N, Cheung F, Hong M, Feng Y. The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases. *Oxidative Medicine and Cellular Longevity*. 2018; 8394818.
24. Abenavoli L, Milic N, Luzzza F, Boccuto L, De Lorenzo A. Polyphenols treatment in patients with nonalcoholic fatty liver disease. *Journal of Translational Internal Medicine*. 2017; 5(3): 144-147.
25. Li W, Zhang K, Yang H. Pectin Alleviates High Fat (Lard) Diet-Induced Nonalcoholic Fatty Liver Disease in Mice: Possible Role of Short-Chain Fatty Acids and Gut Microbiota Regulated by Pectin. *Journal of Agricultural and Food Chemistry*. 2018; 66(30): 8015-8025.
26. Li D, Liu F, Wang X, Li X. Apple Polyphenol Extract Alleviates High-Fat-Diet-Induced Hepatic Steatosis in Male C57BL/6 Mice by Targeting LKB1/AMPK Pathway. *Journal of Agricultural and Food Chemistry*. 2019; 67(44): 12208-12218.
27. Skinner RC, Warren DC, Lateef SN, Benedito VA, Tou JC. Apple pomace consumption favorably alters hepatic lipid metabolism in young female Sprague-Dawley rats fed a western diet. *Nutrients*. 2018; 10(12): 1882.
28. Cho KD, Han CK, Lee BH. Loss of body weight and fat and improved lipid profiles in obese rats fed apple pomace or apple juice concentrate. *Journal of Medicinal Food*. 2013; 16(9): 823-830.
29. Wilkins T, Tadmok A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: Diagnosis and management. *American Family Physician*. 2013; 88(1): 35-42.



This author profile is generated by Scopus. Learn more

Rahniayu, Alphania

[Dr. Soetomo General Academic Hospital, Surabaya, Indonesia](#) [57201077594](#) <https://orcid.org/0000-0002-5059-7875> [View more](#)

15

Citations by 13 documents

10

Documents

2

h-index [View *h*-graph](#)

[Set alert](#)




[Edit profile](#)



[More](#)

Document & citation trends



[Analyze author output](#) [Citation overview](#)

Most contributed Topics 2017–2021

Human Papillomavirus 53; Genotype; Uterine Cervix Carcinoma In Situ

3 documents

Fatty Liver; Proton Density (Concentration); Keratin-18

1 document

Claudins; Tight Junctions; Animals

1 document

[View all Topics](#)

Documents

0 Preprints

25 Co-Authors

5 Topics

0 Awarded Grants

Beta

Documents (10)

Cited by (13)

10 documents

[Export all](#) [Add all to list](#)

Sort by [Date](#) (...

Article

Polymerase chain reaction of human cytomegalovirus from liver and urine compared with serological test in cholestasis infants

0

Citations

Rahniayu, A., Mastutik, G., Rahaju, A.S., ...Sulistiyani, E., Setyoboedi, B.

Journal of Infection in Developing Countries, 2022, 16(10), pp. 1630–1636

[Show abstract](#) [View at Publisher](#) [Related documents](#)

Article

Presentation of Human Cytomegalovirus (HCMV) in Liver Tissues of Cholestatic Infants with Extrahepatic and Non-Extrahepatic Biliary Atresia

0

Citations

Rahniayu, A., Mastutik, G., Sandhika, W., ...Setyoboedi, B., Sulistiyani, E.

Show abstract  View at Publisher  Related documents

Article

Detection of Cytomegalovirus in Urine Specimen of Cholestatic Infants by Polymerase Chain Reaction

2

Citations

Mastutik, G., Kurniasari, N., Rahniayu, A., ...Setyoedi, B., Sulistyani, E.

Research Journal of Pharmacy and Technology, 2022, 15(5), pp. 2151–2157

Show abstract  View at Publisher  Related documents

Article


Role of claudin-4 and matrix metalloproteinase-2 in tumor invasion of colorectal adenocarcinoma

1

Citations

Fatimah, S., Rahaju, A.S., Rahniayu, A.

Research Journal of Pharmacy and Technology, 2021, 14(9), pp. 4795–4800

Show abstract  View at Publisher  Related documents

Article • Open access

p16^{INK4A} Expression in Condyloma Acuminata Lesions Associated with High-Risk Human Papillomavirus Infection

3

Citations

Mastutik, G., Rahniayu, A., Arista, A., ...Rahaju, A.S., Sulistyani, E.

Asian Pacific Journal of Cancer Prevention, 2021, 22(10), pp. 3219–3225

Show abstract  View at Publisher  Related documents

Article

Novel universal primers to identify the expression of mage a1-a10 in the core biopsy of lung cancer

1

Citations

Mastutik, G., Rahniayu, A., Marhana, I.A., ...Amin, M., Putra, S.T.

Middle East Journal of Cancer, 2021, 12(1), pp. 10–19

Show abstract  View at Publisher  Related documents

Article • Open access



Effect of Malus sylvestris extract on histopathological features of hypercholesterolemic wistar rat (Rattus norvegicus) fatty liver

0

Citations

Aufazhafarin, N.T., Rahniayu, A., Qurnianingsih, E., Mustika, A.

Indian Journal of Forensic Medicine and Toxicology, 2021, 15(1), pp. 1367–1372

Show abstract  View at Publisher  Related documents

Article



Correlation between the expression of E6 HPV with P53 and P16INK4A at cervical adenocarcinoma and cervical normal

1

Citations

Mastutik, G., Rahniayu, A., Kurniasari, N., Rahaju, A.S., Alia, R.

Indian Journal of Forensic Medicine and Toxicology, 2021, 15(1), pp. 1827–1834

Show abstract  View at Publisher  Related documents

Article

Non-smoker and non-drinker farmer with oral squamous cell carcinoma

1

Citations

Devianto, H., Desiandrin, T., Radithia, D., Susilo, D.H., Rahniayu, A.

Acta Medica Philippina, 2019, 53(5), pp. 450–453

Show abstract  Related documents

Article

Genotyping of human papillomavirus in cervical precancerous lesion and squamous cell carcinoma at Dr. Soetomo hospital, Surabaya, Indonesia

6

Citations

Mastutik, G., Alia, R., Rahniayu, A., ...Kurniasari, N., Putra, S.T.

African Journal of Infectious Diseases, 2018, 12(Special Issue 1), pp. 7–12

Show abstract  View at Publisher  Related documents

Source details

Indian Journal of Forensic Medicine and Toxicology

Scopus coverage years: from 2008 to Present

(coverage discontinued in Scopus)

Publisher: Institute of Medico-Legal Publications

ISSN: 0973-9122 E-ISSN: 0973-9130

Subject area: Social Sciences: Law Medicine: Pathology and Forensic Medicine

Pharmacology, Toxicology and Pharmaceutics: Toxicology Environmental Science: Health, Toxicology and Mutagenesis

Source type: Journal

CiteScore 2020
0.1

SJR 2020
0.115

SNIP 2020
0.243

[View all documents >](#) [Set document alert](#) [Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology

CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020 ▼

$$0.1 = \frac{387 \text{ Citations 2017 - 2020}}{3,509 \text{ Documents 2017 - 2020}}$$

Calculated on 05 May, 2021

CiteScore rank 2020 ⓘ

Category	Rank	Percentile
Social Sciences		
└ Law	#639/722	11th
Medicine		
└ Pathology and Forensic Medicine	#183/191	4th
Pharmacology,		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)








Indian Journal of Forensic Medicine and Toxicology

Discontinued in Scopus as of 2020

COUNTRY India 	SUBJECT AREA AND CATEGORY Environmental Science Health, Toxicology and Mutagenesis Medicine Pathology and Forensic Medicine Pharmacology, Toxicology and Pharmaceutics Toxicology Social Sciences Law	PUBLISHER Institute of Medico-legal Publications	H-INDEX 12
PUBLICATION TYPE Journals	ISSN 09739122, 09739130	COVERAGE 2008-2021	INFORMATION Homepage How to publish in this journal editor.ijfmt@gmail.com

SCOPE

“Indian Journal of Forensic Medicine & Toxicology ” is a double-blind peer reviewed international journal. The frequency is quarterly. It deals with Forensic Medicine, Forensic Science, Toxicology, DNA fingerprinting, sexual medicine, environmental medicine, Forensic Pathology, legal medicine and public health laws.



Indian Journal of Forensic Medicine and Toxicology

Not yet assigned quartile

SJR 2021: 0

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç"
```

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool.**